Hengrui Medicine (600276. SH) signed a licensing agreement for the HRS-1893 project with Braveheart Bio from the United States.

Zhtng cijng APP xn, Hng ru yyo (600276.SH) fb gnggo, gngs y migu Braveheart Bio, Inc. (yxi jinchng Braveheart Bio) dchng xiy, jing jyu zzh zhchn qun de 1 l chungxn yo HRS-1893 (yxi jinchng HRS-1893) xingm yuchng xk gi Braveheart Bio. Smart Financial APP News, Hengrui Pharmaceutical (600276.SH) announced that the company has reached an agreement with American company Braveheart Bio, Inc. (hereinafter referred to as "Braveheart Bio"), to license the 1st class innovative drug project HRS-1893 with independent intellectual property rights to Braveheart Bio for a fee.